VKTX
NASDAQViking Therapeutics Inc.
News · 26 weeks38-83%
2026-03-012026-08-23
Mix2090d
- Insider7(35%)
- SEC Filings4(20%)
- Earnings3(15%)
- Analyst2(10%)
- Leadership2(10%)
- Other2(10%)
Latest news
25 items- INSIDERDirector Kelly-Gemmell Dorothy Elizabeth was granted 6,333 shares (SEC Form 4)4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kelly-Gemmell Dorothy Elizabeth3 - Viking Therapeutics, Inc. (0001607678) (Issuer)
- SECSEC Form S-3ASR filed by Viking Therapeutics Inc.S-3ASR - Viking Therapeutics, Inc. (0001607678) (Filer)
- INSIDERPresident & CEO Lian Brian sold $4,947,888 worth of shares (148,517 units at $33.32) and was granted 221,667 shares, increasing direct ownership by 3% to 2,572,441 units (SEC Form 4) to satisfy tax liability4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
- INSIDERChief Financial Officer Zante Greg was granted 31,667 shares and sold $710,141 worth of shares (21,217 units at $33.47), increasing direct ownership by 5% to 212,204 units (SEC Form 4) (for tax liability)4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
- INSIDERChief Operating Officer Mancini Marianna was granted 31,667 shares and sold $609,636 worth of shares (18,217 units at $33.47), increasing direct ownership by 3% to 422,760 units (SEC Form 4) (for withholding tax)4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
- SECSEC Form 10-Q filed by Viking Therapeutics Inc.10-Q - Viking Therapeutics, Inc. (0001607678) (Filer)
- SECViking Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Viking Therapeutics, Inc. (0001607678) (Filer)
- PRViking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateConference call scheduled for 4:30 p.m. ET today-- Phase 3 VANQUISH 1 & 2 Trials for Subcutaneous VK2735 in Obesity Fully Enrolled and Advancing ---- Oral Phase 3 VK2735 Trial Initiation Expected 4Q26 ---- VK2735 Maintenance Dosing Data Expected 3Q26 ---- Phase 1 Study of Amylin Agonist VK3019 Underway ---- Strong Quarter-End Cash Position of $502 Million --SAN DIEGO, July 29, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2026, and provided an update o
- SECSEC Form 144 filed by Viking Therapeutics Inc.144 - Viking Therapeutics, Inc. (0001607678) (Subject)
- PRViking Therapeutics Appoints Dorothy Gemmell to Board of DirectorsExperienced Executive Brings Over Two Decades of Leadership Across Healthcare, Digital Health and CommercializationSAN DIEGO,, July 23, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Dorothy Gemmell to its Board of Directors, effective immediately. Ms. Gemmell is a highly experienced executive and board advisor with over 25 years of leadership experience across healthcare, digital health, and commercialization. She has served as president or ch
- PRViking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026Conference Call Scheduled for Wednesday, July 29, at 4:30 p.m. Eastern Time SAN DIEGO, July 22, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the second quarter of 2026 after the market close on Wednesday, July 29, 2026. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, July 29, 2026. To participate in the confe
- PRA Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating UpIssued on behalf of Avaí Bio, Inc. (OTCQB:AVAI)LAS VEGAS, July 21, 2026 /CNW/ -- (American News Group News Commentary) For the millions of people who manage diabetes with daily insulin injections, the holy grail has always been the same: a therapy that senses blood sugar and releases the right amount of insulin on its own, the way a healthy pancreas does. A growing group of biotech companies is chasing that goal with cell-based therapies, and this week one small player took a concrete step toward making its version real. The milestone is a supply deal, which may sound unglamorous, but in cell therapy the source of the cells is
- PRAs AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22Issued on behalf of MindWalk Holdings Corp.MindWalk Holdings Corp. (NASDAQ:HYFT) heads into its fourth-quarter and full-year results with fresh index inclusion, an expanded patent estate, and AI-designed programs aimed at two of medicine's biggest frontiers: GLP-1 metabolic health and infectious disease.AUSTIN, Texas, July 15, 2026 /CNW/ -- Equity Insider News Commentary - Artificial intelligence has moved from the edges of drug discovery to its center. The biggest pharmaceutical companies in the world are now racing to design molecules with machine learning rather than trial and error, and the market has begun to reward the names building the infrastructure underneath that shift. MindWalk H
- PRViking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy AdultsSingle ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019Potential to further expand Viking's treatment options for weight lossSAN DIEGO, June 24, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today the initiation of a Phase 1 single ascending dose (SAD) clinical trial of VK3019, an investigational dual amylin and calcitonin receptor agonist (DACRA). VK3019 is being developed as a potential treatment option for weight loss. The study initiation follows the filing and clearance of VK3019's investi
- PRViking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical OfficerExperienced Biotech Leader with More than Two Decades of Experience Advancing Therapies from Discovery through Regulatory Approval SAN DIEGO, June 11, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Hubert C. Chen, M.D., as chief medical officer. Dr. Chen brings more than two decades of leadership experience in senior executive roles spanning drug discovery, clinical development, regulatory strategy, and product approvals across multiple therapeutic areas. Dr. Chen will report to Brian Lian, Ph.D., presiden
- INSIDERSEC Form 4 filed by Chief Medical Officer Chen Hubert C4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
- INSIDERSEC Form 3 filed by new insider Chen Hubert C3 - Viking Therapeutics, Inc. (0001607678) (Issuer)
- ANALYSTLake Street initiated coverage on Viking Therapeutics with a new price targetLake Street initiated coverage of Viking Therapeutics with a rating of Buy and set a new price target of $89.00
- ANALYSTTruist resumed coverage on Viking Therapeutics with a new price targetTruist resumed coverage of Viking Therapeutics with a rating of Buy and set a new price target of $83.00
- SECViking Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Viking Therapeutics, Inc. (0001607678) (Filer)
- PRViking Therapeutics to Participate at Upcoming Investor ConferencesSAN DIEGO, May 21, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the William Blair 46th Annual Growth Stock Conference and the Jefferies Global Healthcare Conference in June. Details of the company's participation are as follows:William Blair 46th Annual Growth Stock ConferenceDetails: Viking management will deliver a corporate presentation, followed by a breakout session, and partic
- PRNext-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market OpportunitiesAUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (T2DM) rank among the most urgent and costly healthcare problems facing the world today, contributing to surging rates of cardiovascular disease, fatty liver disease, kidney complications and ballooning healthcare expenses. What once represented a specialized class of diabetes treatments has grown into one of the most consequential therapeutic categories in modern medicine, with GLP-1 receptor agonists now fundamentally restructuring how obesity, metabolic disease and potentially even neurodegeneration are treated. Operating in this environment is SureNano Science Ltd. (CSE:S
- PRViking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026Oral VK2735 demonstrated early, progressive weight loss from Week 1 through Week 13 without a plateau Dose-dependent weight loss observed across all VK2735 cohorts, with the highest dose achieving a mean reduction of up to 12.2% (26.6 lbs) from baseline at Week 13Baseline characteristics in the ongoing Phase 3 VANQUISH-1 study of VK2735 in adults with obesity were also presented in a second poster at the conferenceSAN DIEGO, May 12, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today presented additional data from its Phase 2 VENTURE-Oral
- PRViking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026Poster Presentations Highlight Data from 13-Week Phase 2 VENTURE-Oral Trial of VK2735 and Participant Characteristics from Phase 3 VANQUISH-1 Trial of Subcutaneous VK2735 SAN DIEGO, May 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that it will present two posters on its VK2735 program at the 33rd European Congress on Obesity (ECO) taking place in Istanbul, Türkiye on May 12-15, 2026. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors that Viki
VKTX FAQ
7 questionsWhat does Viking Therapeutics Inc. do?
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRÃ), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of...Where does VKTX stock trade?
Viking Therapeutics Inc. (VKTX) is listed on NASDAQ.What sector and industry is VKTX in?
Viking Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Viking Therapeutics Inc. go public?
Viking Therapeutics Inc. (VKTX) completed its IPO in 2015.What are analysts saying about VKTX?
Viking Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Lake Street: Buy on 2026-05-28. Recent price targets range from $3000.00 to $3800.00.What companies are similar to VKTX?
Notable peers in the same industry include LGND (Ligand Pharmaceuticals Incorporated), JNCE (Jounce Therapeutics Inc.), CBAY (CymaBay Therapeutics Inc.), ALRN (Aileron Therapeutics Inc.). Compare VKTX side-by-side with any of them on Quantisnow.How can I track VKTX on Quantisnow?
Quantisnow aggregates Viking Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VKTX to receive live email and push alerts on every new disclosure.